Dr. Raghav on the Utility of Chemotherapy-Free Intervals in CRC


In Partnership With:

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer.

Kanwal Raghav, MBBS, MD, an associate professor in the Department of Gastrointestinal Medical Oncology, of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the utility of chemotherapy-free intervals in colorectal cancer (CRC).

The known adverse effects of chemotherapy forced the field to evaluate chemotherapy-free options, such as single-agent EGFR inhibitors, for patients with CRC, explains Raghav. Additionally, patients can receive a chemotherapy break with bridging therapies such as regorafenib (Stivarga) in the third-line setting, Raghav says.

Chemotherapy-free intervals can allow a patient’s bone marrow to recover from prior chemotherapy, says Raghav. Additionally, data have shown that chemotherapy-free intervals do not diminish patient outcomes. Finally, giving patients a break from chemotherapy could allow them to maintain a good performance status and sustain their eligibility to participate in clinical trials, concludes Raghav.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD